Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gore Links Pharmaceutical Industry To GOP, Bush In Acceptance Speech

Executive Summary

Vice President Al Gore highlighted his willingness to fight pharmaceutical industry pressure as a point of difference between himself and Texas Gov. George W. Bush during his acceptance speech at the Democratic national convention Aug. 17 in Los Angeles.

You may also be interested in...



Medicare Rx Debate Moves To Center Of Presidential Campaigns

The outcome of House/Senate negotiations over drug re-importation and taxpayer funded research will be the most pressing pharmaceutical-related issues in Washington, D.C., as the Medicare drug benefit debate takes center stage in the Presidential campaign.

Medicare Rx Debate Moves To Center Of Presidential Campaigns

The outcome of House/Senate negotiations over drug re-importation and taxpayer funded research will be the most pressing pharmaceutical-related issues in Washington, D.C., as the Medicare drug benefit debate takes center stage in the Presidential campaign.

Democratic VP Nominee Lieberman May Make Election More PhRMA Friendly

The selection of Connecticut Sen. Joseph Lieberman as the Democratic Vice Presidential candidate could make it more difficult for the Gore campaign to make anti-pharmaceutical industry themes a centerpiece of the Presidential campaign.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036519

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel